市場調查報告書

基因治療的全球市場(各類型、用途):產業展望,綜合分析,未來預測

Gene Therapy Market by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024

出版商 Zion Market Research 商品編碼 843100
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
Back to Top
基因治療的全球市場(各類型、用途):產業展望,綜合分析,未來預測 Gene Therapy Market by Type (Somatic Cell Gene Therapy and Germ Cell Gene Therapy) and by Application (Genetic Disorders, Cancer, Cardiovascular Disease, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017-2024
出版日期: 2019年01月15日內容資訊: 英文 110 Pages
簡介

本報告提供全球基因治療市場調查,市場及產業概要,各類型、用途、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

第1章 簡介

  • 報告概要與範圍
  • 調查範圍
  • 調查手法

第2章 摘要整理

  • 市場規模的變化與預測(以金額為準)
  • 市場概述

第3章 產業動態

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 波特的五力分析
  • 市場魅力分析:各市場區隔

第4章 競爭環境

  • 市場佔有率分析
  • 策略趨勢
    • 合併、收購
    • 新材料的登場
    • 協定、夥伴關係、合作、合資企業
    • 研究開發、事業擴大

第5章 基因治療的全球市場:各類型

  • 市場概要
  • 生殖細胞基因治療
  • 體細胞基因治療

第6章 基因治療的全球市場:各用途

  • 市場概要
  • 遺傳基因疾病
  • 癌症
  • 心血管疾病
  • 其他

第7章 基因治療的全球市場:各地區

  • 市場概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第8章 企業簡介

  • UniQure N.V
  • Spark Therapeutics LLC
  • Bluebird Bio
  • Juno Therapeutics
  • GlaxoSmithKline
  • Celgene Corporation
  • Shire Plc
  • Sangamo Biospciences
目錄

The report covers a forecast and an analysis of the gene therapy market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Million). The study includes drivers and restraints of the gene therapy market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the gene therapy market on a global and regional level.

In order to give the users of this report a comprehensive view of the gene therapy market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market including acquisitions mergers, new product launch, agreements, partnerships, collaborations joint ventures, research development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the gene therapy market by segmenting the market based on type, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on the type, the gene therapy market is bifurcated into somatic cell gene therapy and germ cell gene therapy. Based on application, the gene therapy market is classified into genetic disorders, cancer, cardiovascular diseases, and others.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further divided into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

Some key players of the gene therapy market include UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myers Squibb, and Chiesi Farmaceutici S.p.A., among others.

This report segments the global gene therapy market into:

Global Gene Therapy Market: By Type

  • Somatic Cell Gene Therapy
  • Germ Cell Gene Therapy

Global Gene Therapy Market: By Application

  • Genetic Disorders
  • Cancer
  • Cardiovascular Disease
  • Others

Global Gene Therapy Market: By Region

  • North America
  • The U.S.
  • Europe
  • UK
  • France
  • Germany
  • Asia Pacific
  • China
  • Japan
  • India
  • Latin America
  • Brazil
  • Middle East and Africa

Table Of Contents

Chapter 1. Introduction

  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology

Chapter 2. Executive Summary

  • 2.1. Global gene therapy market, 2017 - 2024 (USD Million)
  • 2.2. Global gene therapy market: Snapshot

Chapter 3. Gene Therapy Market - Industry Dynamics

  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global gene therapy market drivers: Impact analysis
    • 3.2.2. The increasing prevalence of genetic disorders and other lifestyle-related life-threatening diseases across the globe
    • 3.2.3. Rising need for gene therapy based targeted treatment
  • 3.3. Market Restraints
    • 3.3.1. Global Gene therapy market restraints: Impact analysis
    • 3.3.2. Need for an individual case-by-case approach
  • 3.4. Opportunities
    • 3.4.1. Increasing adoption of personalized medicines
  • 3.5. Porter's five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. The threat from new entrants
    • 3.5.4. The threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by type
    • 3.6.2. Market attractiveness analysis, by application
    • 3.6.3. Market attractiveness analysis, by region

Chapter 4. Global Gene Therapy Market - Competitive Landscape

  • 4.1. Company Market Share Analysis
    • 4.1.1. Global gene therapy market: company market share, 2017
  • 4.2. Strategic Development
    • 4.2.1. Acquisitions & Mergers
    • 4.2.2. New Product Launch
    • 4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures
    • 4.2.4. Research and Development and Regional Expansion

Chapter 5. Global Gene Therapy Market - Type Analysis

  • 5.1. Global gene therapy market: Type overview
    • 5.1.1. Global gene therapy market revenue share, by Type, 2017 and 2024
  • 5.2. Somatic cell gene therapy
    • 5.2.1. Global gene therapy market for Somatic cell gene therapy, 2017 - 2024 (USD Million)
  • 5.3. Germ cell gene therapy
    • 5.3.1. Global gene therapy market for Germ Cell Gene Therapy, 2017 - 2024 (USD Million)

Chapter 6. Global Gene Therapy Market - Application Analysis

  • 6.1. Global gene therapy market: Application overview
    • 6.1.1. Global gene therapy market revenue share, by Application, 2017 and 2024
  • 6.2. Genetic Disorders
    • 6.2.1. Global gene therapy market for genetic disorders, 2017 - 2024 (USD Million)
  • 6.3. Cancer
    • 6.3.1. Global gene therapy market for Cancer, 2017 - 2024 (USD Million)
  • 6.4. Cardiovascular Disease
    • 6.4.1. Global gene therapy market for Cardiovascular Disease, 2017 - 2024 (USD Million)
  • 6.5. Other Diseases
    • 6.5.1. Global gene therapy market for other diseases, 2017 - 2024 (USD Million)

Chapter 7. Global Gene Therapy Market - Regional Analysis

  • 7.1. Global gene therapy market: Regional overview
    • 7.1.1. Global gene therapy market revenue share, by region, 2017 and 2024
  • 7.2. North America
    • 7.2.1. North America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.2.2. North America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.2.3. The U.S.
      • 7.2.3.1. The U.S. gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.3.2. The U.S. gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.2.4. Canada
      • 7.2.4.1. Canada gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.4.2. Canada gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.2.5. Rest of North America
      • 7.2.5.1. Rest of North America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.2.5.2. Rest of North America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.3.2. Europe gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.3. U.K.
      • 7.3.3.1. U.K. gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.3.2. U.K. gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.4. Germany
      • 7.3.4.1. Germany gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.4.2. Germany gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.5. France
      • 7.3.5.1. France gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.5.2. France gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.6. Italy
      • 7.3.6.1. Italy gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.6.2. Italy gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.7. Spain
      • 7.3.7.1. Spain gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.7.2. Spain gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.8. Russia
      • 7.3.8.1. Russia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.8.2. Russia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.3.9. Rest of Europe
      • 7.3.9.1. Rest of Europe gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.3.9.2. Rest of Europe gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.4.2. Asia Pacific gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.3.2. China gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.4. Japan
      • 7.4.4.1. Japan gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.4.2. Japan gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.5. India
      • 7.4.5.1. India gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.5.2. India gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.6.2. Australia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.4.7. Rest of Asia Pacific
      • 7.4.7.1. Rest of Asia Pacific gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.4.7.2. Rest of Asia Pacific gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America gene therapy market revenue, by type, 2017 - 2024(USD Million)
    • 7.5.2. Latin America gene therapy market revenue, by application, 2017 - 2024(USD Million)
    • 7.5.3. Brazil
      • 7.5.3.1. Brazil gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.3.2. Brazil gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5.4. Mexico
      • 7.5.4.1. Mexico gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.4.2. Mexico gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5.5. Argentina
      • 7.5.5.1. Argentina gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.5.2. Argentina gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.5.6. Rest of Latin America
      • 7.5.6.1. Rest of Latin America gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.5.6.2. Rest of Latin America gene therapy market revenue, by application, 2017 - 2024 (USD Million)
  • 7.6. The Middle East and Africa
    • 7.6.1. The Middle East and Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
    • 7.6.2. The Middle East and Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.3.2. Saudi Arabia gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.4.2. UAE gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.5. South Africa
      • 7.6.5.1. South Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.5.2. South Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.6. Qatar
      • 7.6.6.1. Qatar gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.6.2. Qatar gene therapy market revenue, by application, 2017 - 2024 (USD Million)
    • 7.6.7. Rest of the Middle East and Africa
      • 7.6.7.1. Rest of the Middle East and Africa gene therapy market revenue, by type, 2017 - 2024 (USD Million)
      • 7.6.7.2. Rest of the Middle East and Africa gene therapy market revenue, by application, 2017 - 2024 (USD Million)

Chapter 8. Company Profile

  • 8.1. UniQure N.V
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Therapy portfolio
    • 8.1.4. Business strategy
    • 8.1.5. Recent developments
  • 8.2. Spark Therapeutics LLC
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Therapy portfolio
    • 8.2.4. Business strategy
    • 8.2.5. Recent developments
  • 8.3. Bluebird Bio
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Therapy portfolio
    • 8.3.4. Business strategy
    • 8.3.5. Recent developments
  • 8.4. Juno Therapeutics
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Therapy portfolio
    • 8.4.4. Business strategy
    • 8.4.5. Recent developments
  • 8.5. GlaxoSmithKline
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Therapy portfolio
    • 8.5.4. Business strategy
    • 8.5.5. Recent developments
  • 8.6. Celgene Corporation
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Therapy portfolio
    • 8.6.4. Business strategy
    • 8.6.5. Recent developments
  • 8.7. Shire Plc
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Therapy portfolio
    • 8.7.4. Business strategy
    • 8.7.5. Recent developments
  • 8.8. Sangamo Biosciences
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Therapy portfolio
    • 8.8.4. Business strategy
    • 8.8.5. Recent developments
Back to Top